IT-system Development for Reaching Cervix Cancer Screening Non-attenders

September 30, 2020 updated by: Joakim Dillner, Karolinska Institutet

IT-system Development for Individualization of Cervix Cancer Screening and Implementation of New Strategies to Reach Non-attenders

The main purpose is to develop and test an IT-infrastructure to provide more individualized ways of inviting and reaching women who have not participated, despite having been invited with annual reminders, in cervix cancer screening program during a ten year period.

Study Overview

Detailed Description

BACKGROUND Non-participation in the screening program is the main risk factor for cervical cancer (Andrae et al JNCI, 2008). Therefore it is important to reduce barriers to screening and facilitate participation in the screening program for cervical cancer. Offering self-sampling kits for human papillomavirus (HPV) testing has been examined in several research studies as a way to reach women who have not responded to screening invitations.

Results from a population-based, randomized study in western Sweden concluded that by offering HPV self-sampling kits to screening non-attendees, 17% of cervical cancer cases could be avoided. Offering self-sampling kits to women who have not attended screening in the organized program, can lead to greater participation without substantial increases in the overall health care costs. While there is a growing body of evidence supporting the use of self-sampling, it is unclear how this strategy can be implemented effectively in the context of an organized screening program. An alternative is to offer women the chance to speak with a coordinating midwife who can answer questions and address concerns regarding screening. It is unclear how the results of different research studies should be put into practical use within an organized screening program. Currently, women who have not attended screening are sent an annual reminder invitation. We want to examine whether these alternative strategies (self-sampling and contact with a midwife) may work as well, or better, than current strategy of reminder invitations to non-attenders.

AIM The aim of this randomized health services study is therefore both to test the feasibility of providing alternative strategies instead of the customary reminder invitations to women in Stockholm (so-called feasibility study, primary aim), and whether such strategies will increase overall participation in screening (secondary aim).

STUDY DESIGN AND METHODOLOGY A new IT infrastructure for ordering a self-sampling kit has been developed by LabMed, KI. This in conjunction with the screening database, will be used to identify and invite women who are long-term non-participants in cervical screening. Women who have not participated for ten years, despite annual reminder invitations, will be identified and randomized to one of four strategies.

  1. A validated HPV self-sampling kit will be sent directly to women with a study invitation letter and instructions.
  2. An invitation to order an HPV self-sampling kit through an online application will be sent.
  3. An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent.
  4. The standard annual reminder invitation will be sent (control, routine practice)

Women who choose to participate will be sampled and monitored according to the standards of care in the regional cancer screening program. HPV-positive women will be followed by colposcopy and biopsy according to standard clinical guidelines. Women will be invited over the course of 3 months. All letters will be printed in advance with pre-marked dates. Batches will be sent out weekly and checked against changes in the population registry data (for individuals that have moved, taken a smear, died, or unregistered, invitation letters will be sorted out and those individuals marked in the database).

2 Notation and abbreviations

  • PNR = person nummer, personal ID number 3 Study population 3.1 Inclusion criteria
  • Women who have lived in Stockholm for the past 10 years and have been sent annual reminder at least once per year for 10 years without attending screening.

Specific selection process:

Include women without an "H-prov" on record for the past 10 years Include women have actively been sent a reminder invitation (invitation type=1) during 10 years time. In other words, resident in Stockholm for the past 10 years.

Include women over the age of 33 3.2 Exclusion criteria Women who have opted out of the screening program Hysterectomized Return to sender Changed PNR Women who are marked as Expired=1. Women who have reason marked for being unregistered but are not marked as is unregistered=1.

Women who are due to receive their reminder invitation in the next 3 months 4 Statistical analyses Selection of the study population Randomization A random selection of 8000 women will be chosen from all women meeting the study inclusion criteria.

These 8000 women will be randomized to the 4 study arms (age-stratified 30-50 and 51-60).

The selection of the study population and the randomization to study arms will be carried out by Anna Stoltenberg, Statistician at RCC and outside of the study group 1.

Follow-up - study end date 2016-12-31

Study Type

Interventional

Enrollment (Actual)

8000

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

33 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Non-participants in cervical cancer screening during a 10 year period

Exclusion Criteria:

  • Active refusers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: HPV self sampling test sent
A Cobas PCR (polymerase chain reaction) Female swab sample Packet will be sent directly to women with a study invitation letter and instructions. Response rate will be measured.
The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.
Active Comparator: HPV self sampling test ordered
An invitation to order a Cobas PCR Female swab sample Packet through an online application will be sent. Response rates will be measured.
The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.
Active Comparator: Nurse navigator contact
An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent. The coordinating midwife can help the participant order a Cobas PCR Female swab sample Packet or book a standard screening visit, if desired. Response rates will be measured
The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.
The standard, annual renewed invitation to cervical screening.
Placebo Comparator: Control
The standard, annual renewed invitation to cervical screening will be sent (control, routine practice). Response rate will be measured as a baseline.
The standard, annual renewed invitation to cervical screening.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of women responding (either by and HPV test or a Pap test)
Time Frame: From recruitment until end of study on December 31st 2016 (average 8 months)
Participation rate in screening
From recruitment until end of study on December 31st 2016 (average 8 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Joakim Dillner, MD, Karolinska Institutet

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 14, 2016

Primary Completion (Actual)

December 31, 2016

Study Completion (Anticipated)

December 1, 2021

Study Registration Dates

First Submitted

March 13, 2016

First Submitted That Met QC Criteria

April 22, 2016

First Posted (Estimate)

April 25, 2016

Study Record Updates

Last Update Posted (Actual)

October 5, 2020

Last Update Submitted That Met QC Criteria

September 30, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

Our intention is to share data, but a plan for how this will be done in practise has not been written.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Cancer

Clinical Trials on Cobas PCR Female swab sample Packet

Subscribe